What is Uric Acid?

Uric acid is a natural waste product generated when the body breaks down purines — a group of small biological molecules essential to cell metabolic function (Tang et al., 2019). Purines exist both endogenously (produced inside the body) and exogenously (sourced from foods such as red meat, seafood, and alcohol). The most biologically significant purines are adenine — a building block of DNA and RNA — and the adenosine phosphate molecules: ATP (cellular energy), ADP (energy transfer), and AMP (cell signalling).

Under normal physiological conditions, uric acid is filtered through the kidneys and excreted in urine. Problems arise when production outpaces clearance — a state increasingly linked not to dietary purines, but to the unique way fructose is metabolised and how it drives uric acid production through a distinct enzymatic pathway.

Elevated uric acid is more than a gout marker — it's a window into the metabolic disease patterns elevated uric acid predicts, from insulin resistance Read More to cardiovascular risk.

Normal Uric Acid Reference Ranges (NHS)

Understanding your baseline is the first step. The following reference ranges reflect standard clinical thresholds, though values outside range do not necessarily indicate disease — and values within range do not exclude dysfunction.

How Fructose Drives Uric Acid: The Fructokinase Cascade

Despite strong mechanistic and clinical evidence, fructose is rarely the first cause named when discussing elevated uric acid. The conventional focus falls on dietary purines from red meat and alcohol — yet the enzymatic pathway through which fructose generates uric acid is both faster and less regulated than any purine-containing food (Zhang et al., 2022).

Of all dietary factors, the strongest epidemiological and mechanistic evidence for uric acid elevation points to high-fructose corn syrup as the primary dietary driver of uric acid elevation — particularly via sugar-sweetened beverages, where 355ml cans can deliver 20g+ of free fructose directly to the liver's xanthine oxidase system.

The mechanism begins with fructokinase — the enzyme responsible for the initial phosphorylation of fructose inside the cell. Unlike glucose metabolism, this process has no feedback brake: it runs to completion regardless of cellular energy status, triggering a cascade that ends in uric acid accumulation.

Endogenous Fructose: Why a Low-Sugar Diet May Not Be Enough

One of the most clinically important — and least understood — aspects of uric acid management is the role of endogenous fructose production. Even on a strict low-sugar diet, the body can generate fructose internally through the polyol pathway: a metabolic route that converts glucose to sorbitol, then sorbitol to fructose, entirely independent of dietary intake (Bjornstad et al., 2015).

This internally produced fructose activates fructokinase in exactly the same way as dietary fructose — triggering the same ATP depletion, the same AMP accumulation, and the same uric acid surge. For patients and clinicians puzzled by persistently elevated uric acid despite dietary restriction, the polyol pathway is often the missing explanation.

Beyond Gout: Why High Uric Acid Is a Systemic Problem

Gout remains the most recognised consequence of elevated uric acid — uric acid crystals depositing in joints, causing inflammation, progressive cartilage and bone damage, and the formation of tophi (Ghaemi-Oskouie & Shi, 2011). For a detailed look at how chronic uric acid accumulation damages joint tissue, accelerates bone loss, and how the inflammatory cycle in gout perpetuates itself, the mechanistic picture is clear.

But gout is increasingly understood as just the most visible expression of a much broader metabolic problem. Elevated uric acid — even at levels that never trigger gout — exerts direct vascular, mitochondrial, and inflammatory effects that operate silently across multiple organ systems (Corry et al., 2008; Yip et al., 2020).

Asymptomatic Hyperuricemia: The Silent Metabolic Burden

Perhaps the most clinically significant — and most underappreciated — aspect of uric acid pathophysiology is that it frequently causes no recognisable symptoms until substantial metabolic damage has already occurred. Hyperuricemia is often discovered incidentally through routine blood tests ordered for entirely unrelated reasons (Yip et al., 2020).

While many people — and some clinicians — continue to dismiss asymptomatic hyperuricemia as benign, the mechanistic evidence tells a different story. Elevated uric acid is actively impairing mitochondrial function, driving low-grade systemic inflammation, and degrading insulin sensitivity in the background — even in the complete absence of joint pain or gout attacks.

For individuals being told their slightly elevated uric acid is "not worth treating," an exploration of what the research now shows about subclinical hyperuricemia and the metabolic burden it imposes before any gout symptoms appearoffers important perspective on this evolving clinical question.

The decision to treat or monitor asymptomatic hyperuricemia is a clinical judgement that depends on individual factors including cardiovascular risk, kidney function, and metabolic profile. This content is for educational purposes only. Consult your healthcare provider before making decisions based on your uric acid levels.

Reference: Yip et al. (2020). Asymptomatic hyperuricemia: is it really asymptomatic?Current Opinion in Rheumatology.

Uric Acid and Metabolic Syndrome: A Bidirectional Relationship

The relationship between uric acid and kidney function is one of the most clinically important — and most cyclical — in metabolic medicine. The kidneys are responsible for filtering and excreting uric acid; when they are impaired, uric acid accumulates. But elevated uric acid itself damages the renal vasculature, further impairing filtration capacity. The result is a progressive, self-reinforcing cycle.

Uric acid-driven renal arteriopathy — narrowing and stiffening of the small arteries supplying the kidneys —reduces glomerular filtration rate (GFR) over time. This is separate from gout-related kidney stones, though the two pathways often co-exist. Research examining how uric acid impairs kidney filtration through vascular mechanisms
distinct from crystal deposition — and what this means for long-term renal health reveals a more insidious process than conventional gout literature typically addresses.

Uric acid kidney stones represent a distinct but related risk. When urinary uric acid concentrations exceed solubility thresholds — particularly in acidic urine — uric acid crystalises in the renal tubules and collecting system, forming stones that cause pain, obstruction, and recurrent kidney injury.

Uric Acid, Insulin Resistance & Diabetes

Conventional dietary advice for high uric acid focuses on reducing purine-rich foods — primarily organ meats, shellfish, red meat, and alcohol. This guidance has a scientific basis: dietary purines do contribute to uric acid load. However, the contribution of dietary purines is often modest compared to the contribution of fructose-driven de novo purine synthesis and endogenous production.

What the Evidence Supports?

Foods and beverages most strongly associated with elevated uric acid in clinical studies include high-fructose corn syrup (particularly in sweetened beverages), alcohol (especially beer), organ meats, and concentrated fruit juices. Conversely, dairy products, coffee, and vitamin C have shown modest uric acid-lowering effects in observational research.

For practical guidance on which specific foods drive uric acid accumulation — and the evidence base behind common dietary recommendations for gout and hyperuricemia, the LIV3 research model provides a nuanced breakdown that goes beyond the standard purine avoidance list.

The Fructose Priority

While low-purine dietary strategies have value, addressing fructose intake — both dietary and endogenous — may represent the more impactful upstream intervention. Because fructokinase-driven uric acid production bypasses the regulatory controls that apply to purine metabolism from food, the volume of uric acid that fructose can generate per unit intake substantially exceeds that of most high-purine foods.

Natural Support for Uric Acid Balance: Tart Cherry and Luteolin

Emerging research supports two natural compounds as relevant to uric acid management from complementary angles: reducing production at the enzymatic source, and supporting clearance through anti-inflammatory and renal-protective mechanisms.

Tart Cherry Extract

Tart cherry is rich in anthocyanins —polyphenolic compounds with well-documented anti-inflammatory activity. Clinical studies have shown that tart cherry consumption is associated with reduced serum uric acid levels and decreased markers of inflammation.The proposed mechanisms include both xanthine oxidase inhibition (reducing uric acid production from purine catabolism) and enhanced renal uric acid excretion. For a detailed review of the clinical evidence on tart cherry extract, its proposed mechanisms for reducing uric acid, and its anti-inflammatory activity in hyperuricemia, the research profile is encouraging — particularly for individuals seeking non-pharmacological options.

Luteolin and Fructokinase

Luteolin — a plant flavonoid found in celery, parsley, and chamomile — has demonstrated promise in preclinical models for its capacity to modulate fructokinase activity: the enzyme that initiates the fructose-to-uric-acid cascade (Yao et al., 2023). By targeting the production pathway rather than uric acid itself, luteolin addresses the problem upstream — reducing the volume of uric acid generated from fructose metabolism rather than attempting to manage the downstream accumulation.

A detailed look at the preclinical research on luteolin and fructokinase modulation — and what this suggests for uric acid management in the context of high fructose diets and endogenous fructose production situates this compound within a broader metabolic strategy rather than as a standalone uric acid treatment.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.The information on this page is for educational purposes only and is not a substitute for professional medical advice. If you have been diagnosed with gout, hyperuricemia, kidney disease, or any related condition, consult a qualified healthcare provider before making changes to your diet or supplement regimen.

Addressing Uric Acid at the Source

At LIV3, we believe the most direct strategy for supporting healthy uric acid levels is to address the enzymatic process that generates excess uric acid in the first place. Because fructokinase-driven ATP depletion and de novo purine synthesis are the primary drivers of the modern uric acid epidemic — not dietary purines per se — targeting fructose metabolism upstream represents a fundamentally different approach from traditional uric acid management.

Understanding your biomarkers is step one; supporting them is step two — discover natural compounds that modulate the markers of metabolic dysfunction in our lifestyle hub.

SugarShield delivers liposomal luteolin alongside tart cherry extract — designed to support the body's fructose metabolism from both angles: modulating the fructokinase enzyme at the source of uric acid production, and supporting healthy inflammatory responses downstream through anthocyanin activity. Together, these ingredients represent a nutritional strategy to manage uric acid from both the production and clearance ends, especially when dietary restriction alone is insufficient.*

Continue Exploring the Uric Acid and Metabolic Health Series

• The Complete Fructose Metabolism Guide — foundational science from enzyme to systemic consequence
• Fructokinase: The Enzyme at the Centre of Modern Metabolic Disease — the mechanism behind uric acid production
• How Uric Acid Damages Joints and Drives Gout Progression
• Uric Acid and Cardiovascular Risk: The Renin-Angiotensin Connection
• Uric Acid and Kidney Function: The Cycle That Sustains Itself
• Endogenous Fructose and the Polyol Pathway — why low-sugar diets sometimes fail
• Asymptomatic Hyperuricemia: The Silent Metabolic Burden
• Tart Cherry Extract and Uric Acid: What the Research Shows
• Luteolin and Fructokinase: Targeting Uric Acid at the Source
• Metabolic Syndrome: How Uric Acid Connects the Five Components
• Uric Acid and Insulin Resistance: Breaking the Cycle

References

• Bjornstad, P., Lanaspa, M. A., Ishimoto, T., Kosugi, T., Kume, S., Jalal, D., Maahs, D. M., Snell Bergeon, J. K., Johnson, R. J., & Nakagawa, T. (2015). Fructose and uric acid in diabetic nephropathy. Diabetologia, 58(9), 1993–2002. https://doi.org/10.1007/s00125-015 3650-4
• Chenhao Yao , Shu Dai , Cheng Wang , Ke Fu , Rui Wu , Xingtao Zhao , Yuxin Yao , Yunxia Li. (2023) Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies. Biomedicine & Pharmacotherapy, 167(115464). https://doi.org/10.1016/j.biopha.2023.115464
• Copur, S., Demiray, A., & Kanbay, M. (2022). Uric acid in metabolic syndrome: Does uric acid have a definitive role? European journal of internal medicine, 103, 4-12. https://doi.org/10.1016/j.ejim.2022.04.022
• Corry, Dalila; Eslami, Piroozb; Yamamoto, Keib; Nyby, Michael; Makino, Hirofumi; Tuck, Michael. (2008). Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular
  renin–angiotensin system. Journal of Hypertension, 26(2), 269-275. DOI: 10.1097/HJH.0b013e3282f240bf
• Ghaemi-Oskouie, F., & Shi, Y. (2011). The role of uric acid as an endogenous danger signal in immunity and inflammation. Current rheumatology reports, 13(2), 160-166. https://doi.org/10.1007/s11926-011-0162-1
• João Leonardo Silveira Rossi, Sandra Maria Barbalho, Renan Reverete de Araujo, Marcelo Dib Bechara, Kátia Portero Sloan, Lance Alan Sloan. (2022). Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes metabolism research and reviews, 38(3). https://doi.org/10.1002/dmrr.3502
• Lanaspa, M. A., Ishimoto, T., Cicerchi, C., Tamura, Y., Roncal-Jimenez, C. A., Chen, W., Tanabe, K., Andres-Hernando, A., Orlicky, D. J., Finol, E., Inaba, S., Li, N., Rivard, C. J.,, & Kosugi, T., Sanchez-Lozada, L.
  G., Petrash, J. M., Sautin, Y. Y., Ejaz, A. A., Kitagawa, W., Garcia, G. E., … Johnson, R. J. (2014). Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. Journal of the American Society of Nephrology : JASN, 25(11), 2526–2538. https://doi.org/10.1681/ASN.2013080901
• Tang, Z., Ye, W., Chen, H., Kuang, X., Guo, J., Xiang, M., Peng, C., Chen,
  X., & Liu, H. (2019). Role of purines in regulation of metabolic reprogramming. Purinergic signalling, 15(4), 423-438. https://doi.org/10.1007/s11302-019-09676-z
• Yip, K., Cohen, R. E., & Pillinger, M. H.(2020). Asymptomatic hyperuricemia: is it really asymptomatic? Current opinion in rheumatology, 32(1), 71-79. https://doi.org/10.1097/BOR.0000000000000679
• Zhang, P., Sun, H., Cheng, X., Li, Y., Zhao, Y., Mei, W., Wei, X., Zhou, H., Du, Y., & Zeng, C. (2022). Dietary intake of fructose increases purine de novo synthesis: A crucial mechanism for hyperuricemia. Frontiers in nutrition, 9(1045805). https://doi.org/10.3389/fnut.2022.1045805
• Zhang, S., Wang, Y., Cheng, J., Huangfu, N., Zhao, R., Xu, Z., Zhang, F., Zheng, W., & Zhang, D. (2019). Hyperuricemia and Cardiovascular Disease. Current pharmaceutical design, 25(6), 700-709. https://doi.org/10.2174/1381612825666190408122557